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PEG-lipid degradationTo address the issue of excess polyethylene glycol (PEG)-lipid degradation observed when PEG-modiﬁed lipo-
somes are prepared using the pH-gradient method, a concept using a novel PEG-modiﬁcation method, called
the post-modiﬁcation method, was proposed and evaluated. To assess the proof concept, a preservation–stability
study and a pharmacokinetic study were performed that compared the conventional PEG-modiﬁcation method,
called the pre-modiﬁcationmethod, with the post-modiﬁcationmethod. The results show that PEG-lipid degrada-
tion could be markedly inhibited in the post-modiﬁcation method. Furthermore, the post-modiﬁcation method
could be used without any manufacturing process difﬁculties, especially with high PEG-lipid content. In addition,
a higher blood circulation capability was observed in the post-modiﬁcationmethod. Through comparative studies,
it was found that the post-modiﬁcation method was advantageous compared to the pre-modiﬁcation method. In
conclusion, the post-modiﬁcation method has the potential to be a novel PEG-modiﬁcation method that can
achieve a higher preservation stability of PEG-lipid, a greater ease ofmanufacturing, and a higher blood circulation
capability, especially in the manufacturing of pH-gradient liposomal products.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Drug delivery system studies currently focus on achieving selective
delivery and distribution of drugs to the target disease sites to enhance
safety and effectiveness. Therefore, the feasibility of various particulate
systems, such as liposomes, emulsions, lipidmicrospheres, and polymeric
nanoparticles, has been evaluated as potentially effective drug delivery
systems [1–3].
To selectively deliver an encapsulated drug to the target site, the
control of its pharmacokinetics is essential. The clearance of lipo-
somes is thought to occur through their capture by the mononuclear
phagocyte system (MPS), which takes up and removes liposomes cir-
culating in the blood stream. To prolong circulation time in the blood,
it is especially important to avoid capture by the phagocytic cells in
the liver and spleen. Various characteristics of liposomes affect circu-
lation time in the blood, including chain length, unsaturation of lipids,
lipid composition, size, and Zeta-potential [4–6]. Among these, liposome
membrane surface modiﬁcation using monosialoganglioside GM1 or
polyethylene glycol (PEG)-conjugated lipid (PEG-lipid) has been shown
to greatly improve blood circulation capability [7,8]. Based on these ﬁnd-
ings, various surface modiﬁcation approaches have been investigated to
develop effective liposome-based drug delivery systems.
Since PEG is a highly hydrophilic polymer with very low toxicity, PEG
and its derivatives have been widely used to improve the stability and
pharmacokinetics of drug carriers and parent drugs [9]. In liposomal+81 465 81 4114.
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rights reserved.drug delivery, PEG-lipid has been widely used for liposome surface mod-
iﬁcation (PEGylation), and this technique has already been used for the
preparation of liposomal drug delivery systems, which are known as
PEGylated liposomes [10–23]. Speciﬁcally, doxorubicin-loaded PEGylated
liposomes (Doxil®) have a strongpharmacological effect and low toxicity.
Therefore, these have been widely used in clinical applications and are
approved inmore than80 countries for cancer treatment [24,25]. Toman-
ufacture this product, a unique technology known as the pH-gradient
method has been utilized to achieve high drug loading efﬁciency [26–29].
To achieve high blood circulation capability using PEGylated lipo-
somes, it is important tomaintain the physiological and physicochemical
stability of PEG-lipid. To our knowledge, however, excess PEG-lipid deg-
radation has been observed, especially in PEGylated liposomes prepared
using the pH-gradient method. In general, phospholipids are a compo-
nent of PEG-lipid and this group is easily hydrolyzed in a bell-shaped
manner, with greatest stability at around neutral pH [30]. Unfortunately,
PEG-lipid located on the inner surface of liposomes is ineffective and its
hydrolysatemay cause an increase inmembrane permeability. However,
this has not been well studied. As described, PEG-modiﬁcation and the
pH-gradient method are both essential for liposomal drug delivery, and
these technologies are often used together, such as with Doxil®. There-
fore, these issues need to be resolved.
In this study,wepropose a new concept (the post-modiﬁcationmeth-
od) to avoid excess PEG-lipid degradation, which is observed when
PEGylated liposomes are prepared using the pH-gradient method. The
advantage of this method is that it modiﬁes the PEG-lipid only on the
outer surface of liposomes, thereby avoiding exposure of the PEG-lipid
to low pH conditions.
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for our novel preparation method. The post-modiﬁcation method and
conventional PEG-modiﬁcation method, called the pre-modiﬁcation
method, were compared in terms of stability, ease of manufacturing,
and blood circulation capability, using doxorubicin and vincristine as
model drugs. The results are discussed with regard to the shielding
effect of PEG-lipid, PEG-lipid location, PEG-lipid degradation ratio and
pharmacokinetics.2. Materials and methods
2.1. Materials
Hydrogenated soy phosphatidylcholine (HSPC) was obtained from
Lipoid GmbH (Ludwigshafen, Germany), cholesterol (Chol) was
obtained from Solvay Pharmaceuticals (Nieuweweg, Netherlands),
methoxypolyethyleneglycol (Mw 5000)-DSPE (PEG-lipid) was obtained
from NOF Corporation (Tokyo, Japan), doxorubicin hydrochloride (DXR)
was obtained from RPG Life Science Limited (Maharashtra, India), and
vincristine sulfate (VCR) was obtained from Changzhou Leo Chemical
(Jiangsu, China). All other chemicals used were of analytical grade.2.2. Preparation of DXR liposomes by the pre- and post-modiﬁcation
methods
2.2.1. DXR liposomes prepared using the pre-modiﬁcation method
PEGylated liposomes composed of HSPC and Chol (molar ratio, 54:46)
and a givenmol% of PEG-lipid (0.5, 1.0, 1.5, and 2.0 mol%) were prepared
as follows. HSPC (0.7 g), Chol (0.3 g) and PEG-lipid (0.05–0.20 g) were
dissolved in ethanol (1 ml) at 68 °C and hydrated in a 250 mM aqueous
solution of ammonium sulfate (9 ml) for 15 minutes at 68 °C to yield
crude liposomes. The obtained crude liposomes were extruded through
2 stacked polycarbonate membranes with pore sizes of 200 nm and
100 nm using Extruder T10. DXR loading into liposomes was performed
at a DXR/total lipid molar ratio of 0.16 and incubated at 65 °C for
30 minutes according to previous reports [31,32]. Unloaded DXR was re-
moved using the Sepharose 4 Fast Flow column (GEHealthcare, UK)with
10% sucrose and 10 mM histidine solution (pH 6.5) as an eluent. Sterile
ﬁltration using a 0.2-μm membrane ﬁlter (Minisart Plus; Sartorius,
Goettingen, Germany) was then carried out for PEGylated liposomes
loaded with DXR.
As described above, in the pre-modiﬁcationmethod, the PEGylation
processwas conducted concurrentlywith the downsizing process. Con-
versely, in the post-modiﬁcation method, PEGylation was conducted
after the downsizing process, so that the applied processing condition
could directly affect the success or failure of PEGylation [31].2.2.2. DXR liposomes prepared using the post-modiﬁcation method
Bare liposomes (non-PEGylated liposomes) composed of HSPC and
Chol (molar ratio, 54:46) were prepared as follows. HSPC (7.0 g) and
Chol (2.9 g) were dissolved in ethanol (10 ml) at 68 °C and hydrated
in a 250 mM aqueous solution of ammonium sulfate (90 ml) for
15 minutes at 68 °C to yield crude liposomes. The obtained crude lipo-
somes were extruded through 2 stacked polycarbonate membranes
with pore sizes of 200 nm and 100 nm using Extruder T100.
PEG-lipid aqueous solution (36.74 mg/ml) was then added to the
liposome suspension and heated at 65 °C for 30 minutes to yield
PEGylated liposomes with the desired PEG-lipid mol% (0.25, 0.5, 0.75,
1.0, and 2.0 mol%). It was conﬁrmed that PEG-lipid molecules were
completely incorporated into the liposomal membrane under the ex-
perimental conditions. DXR loading into liposomes was performed at
a DXR/total lipid molar ratio of 0.16 and incubated at 65 °C for 30 mi-
nutes according to previous reports [31,32]. UnloadedDXRwas removed
as described in Section 2.2.1.2.3. Preparation of DXR and VCR liposomes for stability and pharmacoki-
netic study
2.3.1. PEGylated liposomes prepared using the pre-modiﬁcation method
HSPC (0.7 g), Chol (0.3 g), and PEG-lipid (0.15 g) (molar ratio,
54:46:1.5) were dissolved in ethanol (1 ml) at 70 °C and hydrated in a
250 mM citrate buffer sucrose solution (pH 2.5, 500 mOsm) (9 ml) to
yield crude liposomes. The same process described in Section 2.2.1 was
then conducted.
2.3.2. PEGylated liposomes prepared using the post-modiﬁcation method
HSPC (0.7 g) and Chol (0.3 g) (molar ratio, 54:46) were dissolved
in ethanol (1 ml) at 70 °C and hydrated in a 250 mM citrate buffer
sucrose solution (pH 2.5, 500 mOsm) (9 ml) to yield crude liposomes.
The same process described in Section 2.2.2 was then conducted.
2.3.3. DXR- and VCR-loaded-PEGylated liposomes
DXR loading into PEGylated liposomes was performed at a DXR/HSPC
weight ratio of 0.14 and incubated at 65 °C for 30 minutes according to
previous reports [31,32]. VCR loading into PEGylated liposomes was
performed at a VCR/HSPC weight ratio of 0.22. Unloaded DXR and VCR
were removed as described in Section 2.2.1.
2.4. Characterization of various liposomes
2.4.1. Determination of DXR concentration
The total DXR concentration in liposomes was determined by high
performance liquid chromatography (HPLC). Brieﬂy, 100 μl of DXR lipo-
somes was completely dissolved in 2 ml of methanol to analyze total
DXR concentration. A designated amount of DXR was dissolved sepa-
rately in methanol to make solutions of varying concentrations for the
preparation of the standard curve. For these prepared solutions, analysis
of DXR was performed according to the following: column, Inertsil
ODS-2 (4.6×250 mm, 5 μm, GL Science); column temperature, 40 °C;
mobile phase, phosphate solution containing sodium lauryl sulfate/
acetonitrile (1/1); and ﬂow rate, approximately 1.0 ml/minute. An en-
capsulation efﬁciency of DXRwas calculated from these results according
to the following formula:
Encapsulation efficiency of DXR %ð Þ
¼ Total DXR concentration=HSPC concentration½ =0:14 100
2.4.2. Determination of VCR concentration
The total VCR concentration in liposomes was determined by
HPLC. Brieﬂy, 100 μl of VCR liposomes were completely dissolved in
2 ml of methanol to analyze total VCR concentration. A designated
amount of VCR was dissolved separately in methanol to make solutions
of varying concentrations for the preparation of the standard curve. For
these prepared solutions, analysis of VCR was performed according to
the following HPLC conditions: column, Inertsil C8 (4.6×250 mm, 5 μm,
GL Science); column temperature, 40 °C; mobile phase, phosphate
solution/diethylamine/methanol (59/1/140); ﬂow rate, approximately
1.0 ml/min. An encapsulation efﬁciency of VCR was calculated from
these results according to the following formula:
Encapsulation efficiency of VCR %ð Þ
¼ Total VCR concentration=HSPC concentration½ =0:22 100
2.4.3. Determination of the lipid component in liposomal preparations
HSPC, Chol, and PEG-lipid were analyzed by HPLC [31]. Brieﬂy, the
liposomal sample was dissolved in a mixture of water, chloroform, and
2-propanol. Standard solutions of HSPC, Chol, and PEG-lipid were pre-
pared separately. The lipid component of the prepared solutions was
determined using the following HPLC conditions: column, Inertsil Ph
Fig. 1. PEGylation process involving the post-modiﬁcation method at various tempera-
tures. PEG solution was added in the liposomal suspension to attain a concentration of
0.75 mol% against total lipid (HSPC and Chol), and incubated at 25 °C (×), 35 °C (○),
55 °C (△), and 65 °C (□).
2803K. Nakamura et al. / Biochimica et Biophysica Acta 1818 (2012) 2801–2807column (4.6×250 mm, 5 μm,GL Science);mobile phase, acetate buffer/
methanol/ethanol; detector, refractive index detector (Shimadzu, Japan);
ﬂow rate, approximately 1 ml/min.
The PEG-modiﬁcation ratio was calculated according to the fol-
lowing formula:
PEG−modification ratio mol%ð Þ ¼ measured PEG−lipid molð Þ
=½measured HSPC molð Þ þmeasured Chol molð Þ  100
2.4.4. Other methods
HSPC concentration was determined using the Phospholipid C-test
Wako® (Wako Pure Chemicals Ltd., Tokyo, Japan). Particle size and
Zeta-potential were determined using Zetasizer 3000HS (Malvern In-
struments, UK). To measure particle size (nm), 20 μl of liposomes was
diluted with 3 ml of physiological saline solution, and 20 μl of lipo-
somes and PBS were diluted with 2.5 ml of puriﬁed water to measure
Zeta-potential.
2.5. Comparison studies to compare the pre- and post-modiﬁcationmethods
2.5.1. Accelerated preservation stability study
The liposomal dispersions were stored at 40 °C and 75% relative
humidity (RH) for 2 weeks, and the accelerated preservation stability
and Zeta-potential were measured at different time periods. The lipo-
somal dispersions were stored at 25 °C for 4 weeks for the accelerat-
ed preservation stability, and the residual ratio of HSPC and PEG-lipid
were measured at different time periods.
2.5.2. Pharmacokinetics study
This study was conducted at Terumo Corporation (Kanagawa,
Japan) and complied with the regulations of the Committee on Ethics
in the Care and Use of Laboratory Animals. Male Sprague–Dawley rats
aged 6 weeks were purchased from Charles River Co., Ltd. (Kanagawa,
Japan). Animalswere housed in rooms controlled between 23±1 °C and
55±5% RH, and animals had free access to water and food during accli-
matization. To administer the drug at a concentration of 1.0 μmol/ml,
DXR liposomes (pre- and post-modiﬁcationmethod) andVCR liposomes
(pre- and post-modiﬁcationmethod)were dilutedwith 10% sucrose and
10 mMhistidine solution (pH 6.5) before administration. These diluted
DXR (pre- and post-modiﬁcationmethod) andVCR liposomes (pre- and
post-modiﬁcationmethod)were injected into the tail vein of the rat at a
dose of 1.45 mg/kg (2.5 μmol/kg) for DXR (n=3) and 2.31 mg/kg
(2.5 μmol/kg) for VCR (n=3). At 0.25, 1, 2, 4, 6, 8, 12, and 24 hours
after administration, 0.2 ml of blood was taken with a heparinized sy-
ringe and centrifuged for 10 minutes at 5000 rpm and 4 °C to obtain
plasma. The plasma (40 μl)was added tomethanol (100 μl), and the so-
lutionwas centrifuged for 10 minutes at 3500 rpm and 4 °C. The super-
natant was used for the determination of drug concentration in plasma,
andwas kept at−20 °C or lower until use. DXR and VCR concentrations
in the plasmawere determined byHPLC using only results for total drug
concentration, which is a summation of drug loaded into the liposomes
and free drug in the plasma. Aﬂuorophotometer (Shimadzu, Japan)was
used as the detector to analyze DXR concentration in plasma samples,
and an ultraviolet absorption photometer (Shimadzu, Japan) was used
to analyze VCR concentration in plasma samples.
The area under the plasma concentration-versus-time curve (AUC)
was calculated using the trapezoidal rule, and other pharmacokinetic pa-
rameters (half-life [t1/2], volume of distribution [Vd], and clearance [CL])
were calculated with WINNON LIN using one-compartment model.
2.5.3. Statistical analysis
For group comparisons, one-way analysis of variance (ANOVA)with
duplicationwas applied. Signiﬁcant differences in themean valueswere
evaluated using the Student's unpaired t-test. A p-value of less than 0.05
was considered signiﬁcant.3. Results and discussion
3.1. Optimization of temperature conditions for the post-modiﬁcation
process
Before starting the main series of experiments, the inﬂuence of tem-
perature conditions on PEGylationwas investigated toﬁnd a feasible tem-
perature and processing time to ensure the PEG-lipid was modiﬁed onto
bare liposomes. As shown in Fig. 1, the PEG-modiﬁcation ratiowas plotted
as a function of processing time at different temperatures. Above
the phase transition temperature of the liposomal membrane (55 °C
and 65 °C), PEG-lipid was incorporated onto bare liposomes within
10 minutes. No modiﬁcation occurred below the phase transition tem-
perature (25 °C), andmodiﬁcation proceeded slowly near the phase tran-
sition temperature (35 °C). These results suggest that the temperature of
the PEGylation process must be above the phase transition temperature
to achieve a high PEG-modiﬁcation ratio. Consequently, the temperature
condition for the PEGylation process was set at 65 °C for 30 minutes.
In this study, designated amounts of PEG-lipid solutions were
added to bare liposomes for PEGylation (PEG-lipid additive amount).
Unmodiﬁed PEG-lipids were eliminated by gel permeation chromatog-
raphy after PEGylation, and the actual amount of modiﬁed PEG-lipid
was evaluated from the PEGylated liposomes that were obtained. Fig. 2
shows the relationship between the additive amount and the modiﬁed
amount of the PEG-lipid in the post-modiﬁcation method. As seen in
Fig. 2, a high linear correlation was observed with an additive amount
of PEG-lipid of between 0 and 2.7 mol%, with a linear slope of 0.89 and
a multiple correlation coefﬁcient of 0.997.
In previous studies, we found that PEGylated liposomes prepared by
the pre-modiﬁcation method did not pass through the ﬁlter pores
owing to their high viscosity when a high concentration of PEG-lipid
(more than 2.0 mol%) was added [31]. This is a serious issue in the
manufacturing process. Conversely, in the post-modiﬁcation method,
the liposomes were guaranteed to pass through the ﬁlter pores because
high viscosity PEG-lipid was not used. From a practical point of view,
the post-modiﬁcation method is more advantageous compared to the
pre-modiﬁcation method because of the ease of manufacturing of
PEGylated liposomes, especiallywhenPEG-lipid contentswith higher vis-
cosity are added.
These results suggest that the proposed PEGylation method, the
post-modiﬁcation method, may be a simple and reliable manufactur-
ing technology.
3.2. Characterization of various DXR liposomes for the
preservation–stability study
Various DXR liposomes were prepared using the pre- or post-
modiﬁcation method. The Zeta-potential and particle size results are
Fig. 2. The relation between applied PEG-lipid andmodiﬁed PEG-lipid. Different amounts
of PEG-lipid solution were added to bare liposomes for PEGylation, and unmodiﬁed
PEG-lipids were eliminated by gel permeation chromatography after PEGylation.
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Zeta-potential decreasedwith increasing PEG-lipid content to a constant
level of approximately−4 mV. This negative charge density came from
the PEG-lipid and is thought to be balanced by the charge-shielding ef-
fect of PEG-chains. No clear differences in the change in Zeta-potential
between the pre- and post-modiﬁcationmethodswere observed. In con-
trast, as seen in Fig. 3(B), particle size increasedwith increasing PEG-lipid
content of up to approximately 130 nm in the post-modiﬁcation meth-
od. However, no clear changes were observed in the pre-modiﬁcation
method. This behavior is reasonable because the sizing process is initiat-
ed after PEGylation in the pre-modiﬁcationmethod, and theﬁnal particle
size is thereby adjusted to the intended size, irrespective of the PEG-lipid
content. Conversely, the sizing process is initiated before PEGylation in
the post-modiﬁcation method, and the ﬁnal particle size is thereby
directly affected by the PEG-lipid content. Considering that the chain
length of the PEG-lipid that was used (MW: 5000) is approximately
5 nm [17], the observed increase in particle size could be further
evidenced, showing that the added PEG-lipidsweremodiﬁed onto the li-
posomal membrane.
Particle size is a main factor affecting pharmacokinetics. As seen in
Fig. 3(B), the observed increase in particle size is due to an increase in
the thickness of the PEG layers. The diameter of liposomes without PEG
layers (bare liposomes), rather than the diameter of liposomes with
PEG layers, are able to affect pharmacokinetics. Therefore, the increase
in the liposomal diameter after the PEGylation process does not affect
the pharmacokinetics of liposomes.((A) Zeta-potential
0.0 0.5 1.0 1.5 2.0 2.5
Fig. 3. Characterization of DXR liposomes in relation to PEG-lipid content. (A): Zeta-potentia
od (△) and the post-modiﬁcation method (○). Data are represented as the mean (n=3).3.3. Time-dependent change in Zeta-potential during the
preservation-stability study
It is generally known that HSPC is partly hydrolyzed into
lysophosphatidylcholine (Lyso-PC) and fatty acids at high temperatures
and at low pH [30]. Therefore, it is assumed that the negative Zeta-
potential of bare liposomes decreases with time owing to HSPC hydro-
lysis. In contrast, it is assumed that PEGylated liposomes provide lower
negative Zeta-potential values than bare liposomes because of the
charge-shielding effect provided by hydrated PEG chains covering the
negatively charged surface [33,34].
To examine the difference in the charge-shielding effect, the time-
dependent change in Zeta-potential values during preservation was
performed at 40 °C and 75% RH using various liposomal formulations
with different PEG-lipid contents. As shown in Fig. 4, the changes in
Zeta-potential values with PEG-lipid content were compared separately
between liposome formulations prepared using the pre- or post-
modiﬁcation method at 0, 1, and 2 weeks after storage. Immediately
after preparation, all formulations provided only low Zeta-potential
(approximately −4 mV), and there was no clear difference in Zeta-
potential between the 2 preparation methods, irrespective of PEG-
lipid content [Fig. 4 (A)], suggesting that liposomal surface charge is es-
sentially the same atweek 0. However, after 1 week of storage, a drastic
change in the Zeta-potential was observed in bare liposomes, which de-
creased to −17 mV, and the Zeta-potential decreased with increasing
PEG-lipid content up to a constant level of approximately −5 mV.
[Fig. 4(B)]. This indicates that the incorporation of the PEG-lipid effec-
tively shielded the negative charge generated by the hydrolysis of
HSPC. This effect wasmore pronounced in the post-modiﬁcation meth-
od than in the pre-modiﬁcation method. After 2 weeks of storage, the
shielding effect wasmore clearly observed [Fig 4(C)], with the further in-
creasing negative charge density of bare liposomes effectively suppressed
by the introduction of a small amount of PEG-lipid. It was also noted that
the apparent suppressing effect of the post-modiﬁcationmethodwas su-
perior to the pre-modiﬁcation method (almost double). This ﬁnding
strongly supports our hypothesis that the PEG-lipid is distributed only
on the outer surface of the liposomes in the post-modiﬁcation method,
whereas it is equally distributed on both the inner and outer surfaces in
the pre-modiﬁcation method. Considering that the distribution of PEG-
lipid on the liposomes directly contributes to the charge-shielding effect,
the post-modiﬁcationmethod is thought to bemore feasible. As shown in
Fig. 4(A) and Fig. 4(B), the charge-shielding effect of the liposomes with
0.75 mol% of PEG-lipid prepared using the post-modiﬁcation method
was almost equivalent to the liposomes with 1.5 mol% of PEG-lipid pre-
pared using the pre-modiﬁcation method.B) Particle size
0.0 0.5 1.0 1.5 2.0 2.5
l and (B): Particle size. PEGylated liposomes prepared using the pre-modiﬁcation meth-
PEG-lipid content (mol%)
Pre Post
0 1 20 1 2
PEG-lipid content (mol%)
Pre Post
(A) 0W (B) 1W (C) 2W
Fig. 4. Time-dependent change in Zeta-potential in PEGylated liposomes prepared using the pre- (△) and post-modiﬁcation method (○). Preservation–stability study was
conducted at 40 °C and 75% RH, and stored for (A) 0 weeks, (B) 1 week, and (C) 2 weeks. Data are represented as the mean (n=3).
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pharmacokinetic study
PEGylated liposomes of DXR and VCR were prepared for the stabil-
ity and pharmacokinetic study using the pre- and post-modiﬁcation
methods. Composition, drug content, encapsulation efﬁciency, and par-
ticle size were analyzed and are shown in Table 1. From the results of
the above-mentioned charge-shielding study, the molar ratio of PEG-
lipid was adjusted to 1.5 mol% and 0.75 mol% for the pre- and post-
modiﬁcation methods, respectively, so that the amount of PEG-lipid
attached to the outer surface of the liposomes could be equalized. The
particle size analysis provided a higher value (approximately 20 nm)
in the post-modiﬁcation method than the pre-modiﬁcation method,
as expected from Fig. 3(B).
3.5. Preservation–stability study
To examine the inﬂuence of the preparation method on physico-
chemical stability, a preservation–stability study was performed at
25 °C for 4 weeks for the DXR liposomes prepared using the pre- or
post-modiﬁcation method (Table 1). The results are shown in Fig. 5.
As seen in Fig. 5(A), the degradation of HSPC after 2 weeks was ap-
proximately 10% in both liposomes, but further degradation was not
observed until 4 weeks after.
As seen in Fig. 5(B), approximately 20% of the PEG-lipid in the li-
posomes prepared using the pre-modiﬁcation method was degraded
after 2 weeks, whereas no degradation was observed in the post-
modiﬁcation method after 4 weeks.
The degradation (hydrolysis) rate of PEG-lipid on the inside of the
liposomal membrane is expected to be much faster than that of PEG-
lipid on the outside of liposomes, because the pH of the internal aqueous
phase is kept considerably lowwhen the conventional pH-gradientmeth-
od is utilized.Table 1
Characterization of DXR and VCR liposomes. PEGylated liposomes prepared using the











Pre 54:46:1.5 DXR 95.7 1.15 91.7
Pre 54:46:1.5 VCR 66.8 1.27 89.0
Post 54:46:0.75 DXR 92.1 1.29 114.6
Post 54:46:0.75 VCR 75.0 1.37 113.9HSPC is thought to distribute equally to the inside and outside of
the lipid bilayer in both methods. Therefore, it is reasonable that no
differences in HSPC degradation behavior were observed. Conversely,
clear differences in the stability of the PEG-lipidwere observed between
the pre- and post-modiﬁcation methods, which strongly suggest that
the distribution of PEG-lipid is different between the 2 methods. As
mentioned above, in the pre-modiﬁcation method, PEG-lipid may dis-
tribute equally to the inner and outer surfaces of the liposomal mem-
brane, subjecting the internal PEG-lipid to hydrolysis due to the low
pH of the internal aqueous phase. However, in the post-modiﬁcation
method, PEG-lipid is exclusively located on the outer surface of the lipo-
somes, thus avoiding hydrolysis. Since this is an important ﬁnding to
support our hypothesis, further studywas conducted using a lowermo-
lecularweight PEG-lipid (PEG2000-lipid), and itwas conﬁrmed that both
HSPC and PEG-lipid degradation occurred in the same manner, even
though the PEG molecular weight was lower (data not shown).
3.6. Pharmacokinetic studies
To compare the inﬂuence of liposomes prepared using the pre- or
post-modiﬁcation method on blood circulation capability, pharmaco-
kinetic studies were performed using DXR and VCR liposomes (Table 1).
The drug concentration proﬁles in plasma after intravenous administra-
tion are shown in Fig. 6(A) for DXR liposomes and in Fig. 6(B) for VCR
liposomes. As seen in both ﬁgures, both theDXR andVCR liposomes pre-
pared using the post-modiﬁcation method provided higher drug con-
centrations in plasma than those prepared using the pre-modiﬁcation
method. The calculated pharmacokinetic parameters are shown in
Table 2. There were signiﬁcant differences in AUC and Vd between
liposomes prepared using the pre- and post-modiﬁcation methods
(pb0.05), although statistically signiﬁcant differences in t1/2 were not
seen. These ﬁndings suggest that PEGylated liposomes prepared using
the post-modiﬁcation method are superior to those prepared using
the pre-modiﬁcation method in terms of blood circulation capability.
Interestingly, the CL values for DXR liposomes prepared using the
pre- and post-modiﬁcation methods were the same. DXR can be stably
retained into liposomes because of the formation of a rigid complex be-
tween DXR and ions in the inner aqueous compartment [35–37]. The CL
of DXR may be due to the clearance of liposomes, and there may be no
signiﬁcant differences in the clearance of PEGylated liposomes between
the pre- and post-modiﬁcation methods, although initial distribution
immediately after administration is different because of the observed
signiﬁcant differences in Vd between themethods. Although the reason
has not yet been elucidated, it may be because of the uniformity of
dipil-GEP(B)CPSH(A)
tsoPerPtsoPerP
Fig. 5. Percent of remaining HSPC and PEG-lipid in PEGylated liposomes prepared using the pre- or post-modiﬁcation method after storage at 25 °C for 0, 2, and 4 weeks.
(A) Remaining HSPC and (B) remaining PEG-lipid.
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niﬁcant differences in the CL of VCR liposomes between the pre- and
post-modiﬁcation methods. Compared to DXR, VCR does not form
rigid ion complexes with the ions in the inner aqueous compartment.
This means that VCR is easily released from liposomes, and this hypoth-
esis may be supported by the observed lower CL with VCR than with
DXR. From these considerations, the post-modiﬁcation method might
give a rigid membrane structure and show less drug release from
liposomes, since the CL value is signiﬁcantly less than with the pre-
modiﬁcation method.
It is known that various liposome characteristics can affect the
blood circulation capability, including particle size, surface charge,
and surface modiﬁcations [4–6]. However, there were no clear differ-
ences in particle size, Zeta-potential, and PEG charge-shielding effect
for all liposomes used in this study. Under such circumstances, the
observed results were considered to be quite unusual and it is hy-
pothesized that a more complicated mechanism may be the cause of
this phenomenon. There are 2 possible reasons for this, and further
studies investigating these may be warranted. The ﬁrst possible reason
may be the difference inmembrane permeability induced by the amount
of PEGmodiﬁcation. In a recent report, the drug release rate from vesicles
increased with increasing Chol-PEG content [38]. In the pre-modiﬁcation
method, twice the amount of PEG-lipid is required to achieve the same
charge-shielding effect and, therefore, membrane permeability would
be higher than that in the post-modiﬁcationmethod. The second possible
reason may be the content uniformity of PEG-lipids in PEGylated lipo-
somes. In our recent study, it was suggested that PEGylated liposomes
prepared using the pre-modiﬁcation method had more heterogeneous
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Fig. 6. The drug concentration proﬁles in plasma after intravenous administration of (A
pre-modiﬁcation method (△) and PEGylated liposomes prepared using the post-modiﬁcatithe current study, therefore, it may be possible that a smaller amount
of PEG-lipid-modiﬁed liposomes and an excess amount of PEG-
lipid-modiﬁed liposomes might be intermingled (heterogeneous
sample), even if the average PEG-lipid-modiﬁed ratio is adequate. In
this case, a smaller amount of PEG-lipid-modiﬁed liposomes would not
provide the expected blood circulation capability.
Although various other unknown factors may also be involved in
this phenomenon, the present pharmacokinetic study demonstrated
that the post-modiﬁcation method has a higher blood circulation capa-
bility compared to the pre-modiﬁcation method. Further experiments
are being conducted to investigate these possibilities.
4. Conclusions
Through a series of comparative studies, it was shown that the
newly proposed post-modiﬁcation method could selectively modify
PEG-lipid exclusively on the outer surface of liposomes. It was also
demonstrated that the post-modiﬁcation method effectively enabled a
charge-shielding effect even by the addition of a small amount PEG-
lipid, and that this method could markedly inhibit PEG-lipid degrada-
tion, thereby showing high stability. Furthermore, the post-modiﬁcation
method was used without any manufacturing process difﬁculties, espe-
cially with high PEG-lipid content. In addition, a higher blood circulation
capability was observed in the post-modiﬁcation method. Through com-
parative studies, it is thought that the post-modiﬁcation method would
be more advantageous than the pre-modiﬁcation method.
In conclusion, the post-modiﬁcation method has the potential to
be a novel PEG-modiﬁcation method that can achieve higher preser-




















): DXR liposomes and (B) VCR liposomes. PEGylated liposomes prepared using the
on method (○). Data are presented as the mean±standard deviation (n=3).
Table 2
Pharmacokinetic parameters following intravenous administration of DXR and VCR li-













AUC (mg hour/l) 683.4±18.7 766.3±17.9a 754.8±61.5 937.7±49.3b
t1/2 (hour) 13.0±1.3 11.6±0.2 7.9±0.8 7.7±0.4
Vd (ml/kg) 38.3±1.6 31.3±1.1a 32.4±2.6 24.8±1.4b
CL (ml/hour/kg) 2.05±0.13 1.87±0.03 2.86±0.37 2.23±0.09b
a DXR liposomes (pre) vs DXR liposomes (post), pb0.05.
b VCR liposomes (pre) vs VCR liposomes (post), pb0.05.
2807K. Nakamura et al. / Biochimica et Biophysica Acta 1818 (2012) 2801–2807higher blood circulation capability, especially in the manufacturing of
pH-gradient liposomal products.References
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